Medicus Pharma Ltd. 8-K

What Happened

• On December 29, 2025, Medicus Pharma Ltd. announced it entered an Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC to establish an at-the-market (ATM) equity program.
• Under the agreement the company may offer and sell up to $15,349,674 of its common shares through the Agents. Medicus will pay a sales commission of 3.0% of the gross sales price and, subject to limitations, reimburse the Agents’ reasonable documented costs and legal fees.
• Sales, if any, will be made pursuant to the company’s Form S-3 registration statement filed December 29, 2025, and only after that registration statement is declared effective by the SEC; there is no obligation for the company to sell any shares.

Key Details

• Agreement date: December 29, 2025; Agents: Maxim Group LLC and Yorkville Securities, LLC.
• Aggregate offering capacity: $15,349,674 of common shares.
• Agent commission: 3.0% of gross sales; reimbursement of reasonable documented expenses allowed.
• Shares may be sold as ATM transactions (including on Nasdaq) and the program ends when the aggregate amount is sold or as otherwise provided in the agreement.

Why It Matters

• This ATM program gives Medicus a flexible, on-demand way to raise capital by selling shares into the market over time, which can help fund operations or growth without a single large equity offering.
• For investors, the program can increase share supply if sales occur, potentially affecting share price and dilution; however, the company is not required to sell shares and sales can occur only after SEC effectiveness of the Form S-3 registration.
• Monitor future SEC filings (sales notices and Form 8-Ks) for any actual share sales, amounts sold, and timing to assess dilution and capital-raising impact.